Press Releases

 
Press Releases
  Date Title and Summary View
Jul 26, 2007
WOBURN, Mass.--(BUSINESS WIRE)--July 26, 2007--ArQule, Inc. (Nasdaq: ARQL) today announced that it will report its financial results for the second quarter 2007 on Thursday, August 2, 2007 at 7:00 a.m. (eastern time), and hold a conference call at 9:00 a.m. (eastern time). Dr. Stephen A. Hill, ArQule's president and chief executive officer,...
Jul 18, 2007
WOBURN, Mass.--(BUSINESS WIRE)--July 18, 2007--ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) today announced the closing of the purchase of an additional 502,000 shares of the Company's common stock pursuant to the underwriters' partial exercise of their over-allotment option in connection with the Company's recent offering of com...
Jun 19, 2007
WOBURN, Mass.--(BUSINESS WIRE)--June 19, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced the completion of its offering of 7,000,000 shares of common stock at $7.75 per share, representing an aggregate public offering price of approximately $54.25 million before deducting underwriting discounts, commissions and offering expenses. In conne...
Jun 14, 2007
WOBURN, Mass.--(BUSINESS WIRE)--June 14, 2007--ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) announced today the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $7.75 per share. All of the shares are being offered by ArQule pursuant to an effective shelf registration...
Jun 6, 2007
WOBURN, Mass.--(BUSINESS WIRE)--June 6, 2007--ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) announced today that it has filed a preliminary prospectus supplement to an existing shelf registration statement with the Securities and Exchange Commission relating to a proposed public offering of 7,000,000 shares of its common stock. In...
Jun 2, 2007
WOBURN, Mass.--(BUSINESS WIRE)--June 2, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced data from a Phase 1 trial with ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, demonstrating that treatment with ARQ 197 was very well tolerated over extended dosing periods, with more than 60 percent of patients experiencing part...
May 23, 2007
WOBURN, Mass., May 23, 2007 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, upon being declared effective by the SEC, will allow the Company to sell periodically up to $100 million of its securities in one or more...
May 3, 2007
WOBURN, Mass.--(BUSINESS WIRE)--May 3, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the first quarter of 2007. For the quarter ended March 31, 2007, the Company reported a net loss of $14,504,000 or $0.40 per share, compared with net income of $4,286,000, or $0.12 per share, for the first quarter of...
Apr 27, 2007
WOBURN, Mass.--(BUSINESS WIRE)--April 27, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that it has entered into an exclusive license agreement with Kyowa Hakko Kogyo Co., Ltd. (Kyowa) to develop and commercialize ARQ 197, a small molecule, selective inhibitor of the c-Met receptor tyrosine kinase, in Japan and parts of Asia. ...
Apr 25, 2007
WOBURN, Mass.--(BUSINESS WIRE)--April 25, 2007--ArQule, Inc. (Nasdaq: ARQL) today announced that it will report its financial results for first quarter 2007 on Thursday, May 3, 2007 at 7:00 a.m. (eastern time), and hold a conference call at 9:00 a.m. (eastern time). Dr. Stephen A. Hill, ArQule's president and chief executive officer, will l...
Page: FirstPrevious ...
27
NextLast
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300